RNA-Based Therapy for Cryptosporidium parvum Infection: Proof-of-Concept Studies

Keyphrases

• RNA-based Therapy 100%
• Proof of Concept Study 100%
• Cryptosporidium Parvum 100%
• Single Guide RNA (sgRNA) 100%
• Argonaute 100%
• Cryptosporidiosis 75%
• Nucleoside Diphosphate Kinase 75%
• Cryptosporidium 50%
• Mouse Model 25%
• Infected Cells 25%
• Infectious Diseases 25%
• FDA-approved Drugs 25%
• Cause of Death 25%
• Immunocompromised Patients 25%
• In Vivo Model 25%
• Antisense 25%
• Intestinal Epithelial Cells 25%
• RNA Interference 25%
• Parasite Burden 25%
• SCID Mice 25%
• Days of Treatment 25%
• Novel Therapies 25%
• Acute Phase 25%
• Oocyst Shedding 25%
• Children under 5 Years 25%
• Nitazoxanide 25%
• Lipid Nanoparticles 25%
• Diarrhea in children 25%
• Antisense RNA 25%
• Anticryptosporidial 25%
• Moderate-to-severe Diarrhea 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Cryptosporidiosis 100%
• Single Stranded RNA 100%
• Argonaute Protein 100%
• Nucleoside Diphosphate Kinase 75%
• Cryptosporidium 50%
• Infection 25%
• Mouse Model 25%
• Diarrhea 25%
• Oocyst 25%
• Cryptosporidium parvum 25%
• Complementary RNA 25%
• Solid Lipid Nanoparticle 25%
• Nitazoxanide 25%
• SCID Beige Mouse 25%
• Diseases 25%

Immunology and Microbiology

• Cryptosporidium parvum 100%
• Infection 100%
• Ribonucleic Acid 100%
• Argonaute Protein 66%
• Cryptosporidium 33%
• Antisense 16%
• Mouse Model 16%
• Parasite Load 16%
• Oocyst 16%
• Essential Gene 16%
• SCID Beige Mouse 16%
• RNAI 16%
• In Vitro 16%